natgillin/translations-raw huggingface dataset:
The combination was effective regardless of age, baseline rate of bone turnover, or baseline BMD.
Preotact’i ja hormoonasendusravi kombinatsioon oli tõhus sõltumata vanusest ning luu regeneratsiooni ja resorptsiooni vahekorrast ja luu mineraalsest tihedusest enne ravi algust.
The combination was generally well
Kombinatsioon oli üldiselt hästi
The combination was generally well tolerated.
Kombinatsioon oli üldiselt hästi
The combination with Diacomit should be avoided as it may increase their blood levels, leading to digestive disorders, racing heart and insomnia.
Nende kasutamist koos Diacomit’iga tuleks vältida, sest see võib nende taset veres tõsta, põhjustades seedehäireid, südamepekslemist ja unetust.
The combined administration of docetaxel, cisplatin and 5-fluorouracil in 12 patients with solid tumours had no influence on the pharmacokinetics of each individual medicinal product.
12 soliidtuumoriga patsiendi kombinatsioonravi dotsetakseeli, tsisplatiini ja 5–fluorouratsiiliga ei mõjutanud ühegi individuaalse ravimi farmakokineetikat.
The combined storage time (reconstituted solution in vial and diluted solution in infusion bag) at 25°C must not exceed 12 hours (24 hours if refrigerated).
Kombineeritud aeg (viaal ja infusioonikott) 25°C juures ei tohi ületada 12 tundi (24 tundi külmkapis).
The combined use of Aptivus with ritonavir with either omeprazole, esomeprazole or with other proton pump inhibitors is not recommended (see section 4.5).
Aptivus’e ja ritonaviiri samaaegne kasutamine omeprasooli, esomeprasooli või teiste prootonpumba inhibiitoritega ei ole soovitatav (vt lõik 4.5).
The combined use of Aptivus with ritonavir with either omeprazole, esomeprazole or with other proton pump inhibitors is not recommended (see section 4.5).
Aptivus’e/ritonaviiri samaaegne kasutamine omeprasooli, esomeprasooli või prootonpumba inhibiitoritega ei ole soovitatav (vt lõik 4.5).
The combined use of Aptivus, co-
Aptivus’t ja ritonaviiri väikeseid
The combined use of Aptivus, co-
kombineerimisel soovitatakse
The combined use of Aptivus, co-
võõrutussündroomi osas.
The combined use of Veraflox with theophylline (used with chronic respiratory conditions) or digoxin (used with congestive heart failure) should also be avoided because of potentially higher blood levels which could increase the effects of these drugs.
Kombineeritud kasutamist teofülliniga (kasutatakse krooniliste hingamisteede haiguste puhul) või digoksiiniga (kasutatakse südamehaiguste korral) tuleks vältida potensiaalselt kõrgema plasmasisalduse ja nende koostoime suurenenud efektide tõttu.
The combined use of Veraflox with theophylline (used with chronic respiratory conditions) or digoxin (used with congestive heart failure) should also be avoided because of potentially higher blood levels which could increase the effects of these drugs.
Kombineeritud kasutamist teofülliniga (kasutatakse krooniliste hingamisteede haiguste puhul) või digoksiiniga (kasutatakse südamehaiguste korral) tuleks vältida potensiaalselt kõrgema plasmasisalduse ja nende koostoime suurenenud effektide tõttu.
The combined use of Veraflox with theophylline (used with chronic respiratory conditions) or digoxin (used with congestive heart failure) should also be avoided because of potentially higher blood levels which could increase the effects of these drugs.
Kombineeritud kasutamist teofülliniga (kasutatakse krooniliste hingamisteede haiguste puhul) või digoksiiniga (kasutatakse südamehaiguste korral) tuleks vältida potensiaalselt kõrgema plasmasisalduse tõttu kuna see suurendab nende toimet.
The Committee also acknowledged that there is an unmet medical need for these patients.
Komitee tunnistas ka, et neil patsientidel on täitmata ravivajadus.
The Committee also acknowledged the seriousness of Duchenne muscular dystrophy and the unmet medical need of patients with this condition.
Komitee möönis ka Duchenne’i lihasdüstroofia tõsidust ning selle haigusega patsientide rahuldamata ravivajadust.
The Committee also concluded that the data derived from the COPD studies adequately demonstrated that Relvar Ellipta 92 /22 microgram had a clinically relevant effect on the reduction of COPD flare-ups.
Inimravimite komitee järeldas ka, et kroonilise obstruktiivse kopsuhaiguse uuringute andmed tõestasid piisavalt, et Relvar Ellipta tugevuse 92/22 µg toime kroonilise obstruktiivse kopsuhaiguse ägenemiste vähendamisel oli kliiniliselt oluline.
The Committee also concluded that the data derived from the COPD studies adequately demonstrated that Revinty Ellipta 92 /22 microgram had a clinically relevant effect on the reduction of COPD flare-ups.
Komitee järeldas ka, et kroonilise obstruktiivse kopsuhaiguse uuringute andmed tõestasid piisavalt, et Revinty Ellipta tugevuse 92/22 µg toime kroonilise obstruktiivse kopsuhaiguse ägenemiste vähendamisel oli kliiniliselt oluline.
The Committee also considered that the benefit of Truvada has been shown for pre-exposure prophylaxis but the level of protection depends on how well individuals stick to the recommended dose schedule.
Komitee leidis ka, et tõendatud on Truvada kasulikkus kokkupuute-eelsel ennetamisel, kuid kaitsetase oleneb sellest, kui hästi järgivad isikud soovitatavat annuseskeemi.
The Committee also considered that the benefits of Invega had been shown to be greater than its risks in the treatment of schizophrenia in adolescents from 15 years of age.
Komitee leidis ka, et tõendite alusel on Invega kasulikkus vähemalt 15- aastase noorukite skisofreeniaravis suurem kui sellega kaasnevad riskid.
The Committee also considered that the data available support the use of Olysio in combination with sofosbuvir.
Lisaks leidis komitee, et olemasolevad andmed toetavad Olysio kasutamist koos sofosbuviiriga.
The Committee also considered that, if given before a liver transplant, Sovaldi in combination with ribavirin can prevent re-infection of the liver, which in the absence of treatment occurs nearly always and results in a poor prognosis.
Inimravimite komitee võttis samuti arvesse asjaolu, et kui Sovaldit manustada enne maksasiirdamist, siis võib Sovaldi kombinatsioonis ribaviriiniga ära hoida maksa taasnakatumise, mis tekib ilma ravita praktiliselt kõigil juhtudel ja halvendab oluliselt prognoosi.
The Committee also considered the fact that Zytiga is given by mouth to be a further advantage.
Samuti pidas komitee Zytiga eeliseks selle suukaudset manustamist.
The Committee also decided that the benefits of Aptivus oral solution are greater than its risks for children from two to 12 years of age.
Komitee otsustas ka, et Aptivuse suukaudse lahuse kasulikkus 2–12-aastastel lastel on suurem kui sellega kaasnevad riskid.
The Committee also noted that Activyl Tick Plus combined two active substances thereby reducing the need to use two different products against flea and tick infestations.
Veterinaarravimite komitee märkis samuti, et Activyl Tick Plusi koostisse kuuluva kahe toimeaine tõttu väheneb vajadus kasutada kirpude ja puukide tõrjeks kahte erinevat ravimit.
The Committee also noted that for patients with homozygous familial disease there is an unmet clinical need, as these patients are difficult to treat and have a high risk of cardiovascular disease.
Komitee märkis ka, et homosügootse päriliku haigusega patsientide ravivajadus on rahuldamata , sest neid on raske ravida ja neil on suur kardiovaskulaarse haiguse tekke risk.
The Committee also noted that patients with CLL who had not responded to previous treatment have limited treatment options.
Komitee märkis ka, et neil kroonilise lümfotsütaarse leukeemiaga patsientidel, kellel varasem ravi ravivastust ei tekitanud, on ravivõimalused piiratud.
The Committee also noted that short bowel syndrome is a serious and disabling condition for which only limited symptomatic treatment exists.
Inimravimite komitee märkis veel, et lühikese soole sündroom on raske ja puudega lõppev haigus, mille jaoks on olemas vaid piiratud sümptomaatiline ravi.
The Committee also noted that tazobactam is known not to be active against some classes of beta-lactamase that can cause problems of resistance.
Samuti märkis komitee, et teadaolevalt ei toimi tasobaktaam teatud beetalaktamaaside rühmade suhtes, mis võib põhjustada resistentsusprobleeme.
The Committee also noted that the demonstration of Atripla’s benefit is based mainly on 48-week data from a study in patients with stable suppression of HIV on an HIV treatment combination who then switched to Atripla.
Komitee märkis ka, et Atripla kasulikkust tõendati põhiliselt stabiilse HIV-supressiooniga patsientide ühe 48-nädalase uuringuga, milles HIV-ravimite kombinatsiooni kasutanud patsiendid läksid üle Atripla kasutamisele.
The Committee also noted that the safety profile of Imnovid was considered acceptable for these patients, with side effects similar to those of other medicines of this type.
Komitee märkis samuti, et Imnovidi ohutusprofiili peetakse nende patsientide puhul vastuvõetavaks, sest ravimi kõrvalnähud on sarnased muude sama tüüpi ravimite kõrvalnähtudega.
The Committee also noted that there is little information on the benefits of treatment including a protease inhibitor in patients who have been treated with Stocrin in the past but which stopped working, although there is no evidence to suggest that protease inhibitors may not work in these patients.
Komitee märkis ka, et on vähe teavet proteaasiinhibiitorit sisaldava ravi kasulikkuse kohta patsientidel, keda on varem Stocriniga ravitud, kuid kellele ravi enam ei mõju; samas puuduvad tõendid, et proteaasiinhibiitorid neile patsientidele ei mõju.
The Committee also noted that there is little information on the benefits of treatment including a protease inhibitor in patients who have been treated with Sustiva in the past but which stopped working, although there is no evidence to suggest that protease inhibitors may not work in these patients.
Komitee märkis ka, et on vähe teavet proteaasiinhibiitorit sisaldava ravi kasulikkuse kohta patsientidel, keda on varem Sustivaga ravitud, kuid kellele ravi enam ei mõju, samas puuduvad tõendid, et proteaasiinhibiitorid neile patsientidele mõju ei avalda.
The Committee also noted that treatment with Firmagon does not trigger the temporary sharp rise in testosterone levels seen with ‘GnRH agonists’ (other medicines for prostate cancer that stimulate the production of GnRH).
Komitee märkis ka, et ravi Firmagoniga ei vallanda ajutist äkilist GnRH agonistide (GnRH tootmist stimuleerivad eesnäärmevähi ravis kasutatavad ravimid) kasutamisel täheldatavat testosteroonitaseme tõusu.
The Committee also noted the risk of side effects affecting the kidneys, and recommended that kidney function should be carefully assessed before patients start taking Stribild and should be monitored during treatment.
Inimravimite komitee rõhutas neeru kahjustavate kõrvalnähtude riski ja soovitas, et enne kui patsiendid alustavad Stribildi võtmist, tuleb neerutalitlust hoolikalt hinnata ja seda peab ravi ajal jälgima.
The Committee also recommended that the vaccine be authorised in children from nine to 12 months of age only in certain situations, for example as part of a national vaccination programme, during an outbreak or for travel to a region where measles is common.
Komitee soovitas ka anda loa vaktsiini manustamiseks 9–12-kuustel lastel üksnes teatud olukordades, nt riikliku vaktsineerimisprogrammi raames, haiguspuhangu ajal või kui reisitakse piirkonda, kus leetrid on levinud.
The Committee concluded that benefits of Zelboraf are greater than its risks and recommended that it be granted marketing authorisation.
Inimravimite komitee järeldas, et Zelborafi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The Committee concluded that Imnovid is effective at delaying the progression of multiple myeloma in patients whose disease does not respond to or comes back after previous treatment, who have very limited treatment options.
Inimravimite komitee jõudis järeldusele, et Imnovid on efektiivne hulgimüeloomi süvenemise edasilükkamisel patsientidel, kelle haigus ei allu eelnevale ravile või taastub selle järel ja kelle ravivõimalused on väga piiratud.
The Committee concluded that it also was effective in children.
Komitee järeldas, et see on efektiivne ka laste ravimisel.
The Committee concluded that the effect of Xadago on the daily time that patients lived without motor symptoms was of clinical relevance, also taking into account the response reported in the literature for other Parkinson’s medicines.
Inimravimite komitee järeldas, et Xadago toimel ööpäevas ilma motoorikasümptomiteta saavutatud aeg oli kliiniliselt tähtis, arvestades ka kirjanduses teatatud ravivastust muudele Parkinsoni tõve ravimitele.
The Committee concluded that Truvada’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee järeldas, et Truvada kasulikkus on suurem kui sellega kaasnevad riskid, ning soovitas anda ravimi müügiloa.
The Committee concluded the long experience with the active substance, methylthioninium chloride, shows that it is effective in treating methaemoglobinaemia.
Inimravimite komitee järeldas, et ravimi toimeaine metüültioniinkloriidi kauaaegne kasutuskogemus tõendab, et Methylthioninium chloride Proveblue on methemoglobineemia ravis efektiivne.
The Committee considered that adding this medicine to other diabetes medicines offers better control of blood glucose and having an alternative treatment option is valuable in individualising treatment.
Komitee leidis, et Xultophy lisamine teistele diabeediravimitele aitab vere glükoosisisaldust paremini reguleerida ja ravi individuaalse kohandamise seisukohast on oluline alternatiivse ravivõimaluse olemasolu.
The Committee considered that Bosulif had been shown to be effective at controlling CML in these patients and, although it had important side effects, its safety profile was acceptable as a last treatment option in these patients.
Komitee järeldas, et Bosulif on nendel patsientidel efektiivne kroonilise müeloidleukeemia kontrolli alla saamisel ja kuigi sellel on olulisi kõrvalnähte, oli ravimi ohutusprofiil nende patsientide viimase ravivõimalusena vastuvõetav.
The Committee considered that Mekinist when used alone or in combination with dabrafenib had shown a clinically relevant benefit in patients whose melanoma had a BRAF V600 mutation.
Komitee leidis, et ainsa ravimina või koos dabrafeniibiga kasutava Mekinisti kliiniliselt oluline kasulikkus on tõendatud patsientidel, kel on mutatsiooniga BRAF V600 melanoom.
The Committee considered that Perjeta has been shown to benefit patients with metastatic cancer by extending the amount of time patients lived without their disease getting worse as well as how long they lived.
Komitee arvates on tõestatud, et Perjeta pikendab metastaatilise vähiga patsientide progresseerumiseta elulemust.
The Committee considered that Raplixa is effective at reducing the time to stop mild or moderate bleeding during surgery when standard surgical techniques, such as stitches, are insufficient.
Inimravimite komitee oli seisukohal, et Raplixa on efektiivne operatsioonil vähese või mõõduka verejooksu peatamiseks kuluva aja vähendamisel, kui standardsed kirurgilised meetodid, näiteks õmblused, on ebapiisavad.
The Committee considered that Tafinlar (alone or in combination with trametinib) had shown a clinically relevant benefit in patients whose melanoma had a BRAF V600 mutation and had spread or was not surgically removable.
Inimravimite komitee leidis, et (eraldi või koos trametiniibiga manustatava) Tafinlari kliiniliselt oluline kasulikkus on veenvalt tõendatud patsientidel, kellel on BRAF V600 mutatsiooniga melanoom, millel on siirded või mida ei saa kirurgiliselt eemaldada.
The Committee considered that the benefits of Deltyba had been shown for patients with multi-drug resistant tuberculosis affecting the lung.
Inimravimite komitee leidis, et Deltyba kasulikkus multiresistentse kopsutuberkuloosiga patsientidel on tõestatud.
The Committee considered that Xgeva was shown to be effective in preventing bone-related events and was less toxic to the kidneys and easier to administer than existing treatments.
Komitee leidis, et uuringute põhjal oli Xgeva luudega seotud haigusjuhtude ärahoidmisel efektiivne ning oli neerudele vähem toksiline, samuti on seda võrreldes teiste olemasolevate ravimitega lihtsam manustada.
The Committee decided that Abraxane’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Komitee otsustas, et Abraxane kasulikkus on suurem kui sellega kaasnevad riskid, ning soovitas anda ravimi müügiloa.
The Committee decided that ACOMPLIA’s benefits are greater than its risks when used, in addition to diet and exercise, to treat obese patients and overweight patients with risk factors such as type 2 diabetes or dyslipidaemia.
Komitee otsustas, et ACOMPLIA kasulikkus selle kasutamisel lisaks dieedile ja liikumisele rasvunud patsientide ning ülekaaluliste ja selliste ohuteguritega nagu II tüüpi suhkurtõbi või düslipideemia patsientide raviks on suurem kui sellega kaasnevad riskid.
The Committee decided that Adenuric’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Adenurici kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The Committee decided that Atripla’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Atripla kasulikkus on suurem kui sellega kaasnevad riskid, ning soovitas anda ravimi müügiloa.
The Committee decided that ATryn’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et ATryni kasulikkus on suurem kui sellega kaasnevad riskid, ning soovitas anda ravimi müügiloa.
The Committee decided that Azarga’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Komitee otsustas, et Azarga kasulikkus on suurem kui sellega kaasnevad riskid, ning soovitas anda ravimi müügiloa.
The Committee decided that Benlysta’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Komitee otsustas, et Benlysta kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The Committee decided that Busilvex’s benefits are greater than its risks in these settings and recommended that Busilvex be given marketing authorisation.
Komitee otsustas, et Busilvexi kasulikkus on suurem kui sellega kaasnevad riskid, ning soovitas anda ravimi müügiloa.
The Committee decided that Cerezyme’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Cerezyme kasulikkus on suurem kui sellega kaasnevad riskid, ning soovitas anda ravimi müügiloa.
The Committee decided that Competact’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Competacti kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The Committee decided that Corlentor’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Komitee otsustas, et Corlentori kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The committee decided that Cystadane’s benefits outweighed its risks in the adjunctive treatment of homocystinuria, when it is used according to its indication.
Komitee leidis, et Cystadane kasulikkus kasutamisel vastavalt selle näidustusele homotsüstinuuria täiendava ravina on suurem kui sellega kaasnevad riskid.
The Committee decided that DepoCyte’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et DepoCyte kasulikkus on suurem kui sellega kaasnevad riskid, ning soovitas anda ravimi müügiloa.
The Committee decided that Dukoral’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Dukorali kasulikkus on suurem kui sellega kaasnevad riskid, ning soovitas anda vaktsiini müügiloa.
The Committee decided that Elaprase’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Komitee otsustas, et Elaprase kasulikkus on suurem kui sellega kaasnevad riskid, ning soovitas anda ravimi müügiloa.
The Committee decided that Evista’s benefits are greater than its risks for the treatment and prevention of osteoporosis in postmenopausal women.
Komitee otsustas, et Evista kasulikkus osteoporoosi ennetamisel ja ravis menopausijärgses eas naistel on suurem kui ravimiga kaasnevad riskid.
The Committee decided that Evoltra’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Evoltra kasulikkus on suurem kui sellega kaasnevad riskid, ning soovitas anda ravimi müügiloa.
The Committee decided that Gilenya’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Gilenya kasulikkus on suurem kui sellega kaasnevad riskid, ning soovitas anda ravimi müügiloa.
The Committee decided that Gliolan’s benefits are greater than its risks for the visualisation of malignant tissue during surgery for malignant glioma.
Komitee otsustas, et Gliolani kasulikkus ületab ravimi riske, kui ravimit kasutatakse pahaloomulise glioomi operatiivse ravi ajal kasvajakoe visualiseerimiseks.
The Committee decided that Glubrava’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Komitee otsustas, et Glubrava kasulikkus on suurem kui sellega kaasnevad riskid, ning soovitas anda ravimi müügiloa.
The Committee decided that Invanz’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Komitee otsustas, et Invanzi kasulikkus ületab sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The Committee decided that Ivabradine Anpharm’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Ivabradine Anpharmi kasulikkus on suurem kui sellega kaasnevad riskid, ning soovitas anda ravimi müügiloa.
The Committee decided that Mircera’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Komitee otsustas, et Mircera kasulikkus on suurem kui sellega kaasnevad riskid, ning soovitas anda ravimi müügiloa.
The Committee decided that Noxafil’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Noxafili kasulikkus on suurem kui sellega kaasnevad riskid, ning soovitas anda ravimi müügiloa.
The Committee decided that Onduarp’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Onduarpi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The Committee decided that Optruma’s benefits are greater than its risks for the treatment and prevention of osteoporosis in postmenopausal women.
Komitee otsustas, et Optruma kasulikkus osteoporoosi ennetamisel ja ravis kliimaksijärgses eas naistel on suurem kui sellega kaasnevad riskid.
The Committee decided that Orencia’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Komitee otsustas, et Orencia kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The Committee decided that Posaconazole SP’s benefits are greater than its risks for treatment of invasive aspergillosis, fusariosis, coccidioidomycosis, chromoblastomycosis and mycetoma in patients who cannot tolerate other antifungal drugs or have not improved after at least 7 days of treatment.
Komitee leidis, et Posaconazole SP kasulikkus invasiivse aspergilloosi, fusarioosi, koktsidoidmükoosi, kromoblastomükoosi ja mütsetoomi ravimisel on suurem kui sellega kaasnevad riskid neil patsientidel, kes ei talu muid seenevastaseid ravimeid või kelle haigus ei ole pärast vähemalt 7-päevast ravi paranenud.